Pharmacy Thesis Topics

Pharmacy thesis topics represent a clinically vital and scientifically diverse area within health thesis topics, drawing graduate students at American universities into a discipline that bridges molecular pharmacology, clinical therapeutics, pharmaceutical sciences, and healthcare delivery. Pharmacy encompasses drug discovery and development, pharmacokinetics and pharmacodynamics, pharmaceutical care, medication safety, health outcomes research, and the expanding clinical roles of pharmacists across American healthcare settings. As medication therapy grows more complex, polypharmacy burdens an aging American population, and antimicrobial resistance threatens the efficacy of foundational treatments, the research questions animating pharmacy thesis topics have never been more urgent or consequential for patient safety and public health.

Pharmacy Thesis Topics and Research Areas

The discipline of pharmacy spans the full arc from molecular drug design to population-level medication use policy, requiring graduate students to engage with organic chemistry, biopharmaceutics, clinical pharmacology, health services research, and the regulatory science governing drug approval and post-market surveillance in the United States. From characterizing novel drug delivery systems and investigating pharmacogenomic predictors of drug response to evaluating pharmacist-led intervention programs and analyzing opioid prescribing disparities across American communities, pharmacy thesis topics offer research environments where laboratory precision and clinical relevance are equally valued. The 200 pharmacy thesis topics organized below into 10 thematic categories are designed to be research-ready at American pharmacy schools and graduate programs, each grounded in a specific methodology and pointing toward a defined knowledge gap.

1. Pharmaceutical Sciences and Drug Development

Pharmaceutical sciences address the physical, chemical, and biological foundations of drug design, formulation, stability, and delivery — making this a technically rigorous category of pharmacy thesis topics that underpins the entire drug development enterprise at American research universities and pharmaceutical companies. Research here encompasses medicinal chemistry, biopharmaceutics, nanotechnology-based drug delivery, solid-state characterization, and the analytical methods used to evaluate drug quality across development and manufacturing. Graduate students at American colleges of pharmacy contribute to innovations in drug formulation and delivery that advance the pipeline from laboratory discovery toward clinical application.

1. Investigating the solubility enhancement potential of amorphous solid dispersion formulations for poorly water-soluble BCS Class II drugs using hot-melt extrusion technology and in vitro dissolution testing
2. Analyzing the physicochemical stability and degradation pathways of mRNA vaccine formulations under accelerated storage conditions relevant to American cold chain distribution challenges
3. Developing a lipid nanoparticle delivery system for hepatocyte-targeted siRNA therapeutics and characterizing its encapsulation efficiency, particle size, and in vitro gene silencing activity
4. Characterizing the polymorphic form conversion kinetics of an active pharmaceutical ingredient during wet granulation manufacturing using real-time near-infrared spectroscopy monitoring
5. Investigating the permeability enhancement mechanisms of tight junction modulating excipients for improving oral bioavailability of peptide drug candidates in Caco-2 cell monolayer models
6. Analyzing the co-crystal formation strategies for improving the dissolution rate and bioavailability of a poorly soluble cardiovascular drug candidate using pharmaceutical cocrystal screening methodology
7. Developing a mucoadhesive vaginal drug delivery system for local antifungal therapy with prolonged residence time and evaluating its in vitro drug release and mucoadhesion properties
8. Characterizing the aggregation propensity and colloidal stability determinants of monoclonal antibody formulations under physiologically relevant stress conditions using dynamic light scattering
9. Investigating the drug release mechanisms and in vitro-in vivo correlation of extended-release matrix tablet formulations for a narrow therapeutic index drug using USP dissolution apparatus methodology
10. Analyzing the nanoparticle surface functionalization strategies for improving blood-brain barrier penetration of chemotherapeutic agents in glioblastoma treatment models
11. Developing a spray-dried inhalation powder formulation for a macromolecular biologic drug and characterizing its aerodynamic particle size distribution and in vitro lung deposition
12. Characterizing the excipient-drug interactions affecting chemical stability of a moisture-sensitive active pharmaceutical ingredient in solid oral dosage forms under humidity stress conditions
13. Investigating the self-emulsifying drug delivery system design variables that optimize oral bioavailability enhancement for a lipophilic immunosuppressant drug candidate in rat pharmacokinetic models
14. Analyzing the 3D printing technology parameters for producing personalized dose oral solid dosage forms with patient-specific drug content using fused deposition modeling methodology
15. Developing a targeted polymeric nanoparticle platform for tumor-specific delivery of combination chemotherapy and evaluating its cytotoxicity and cellular uptake in cancer cell line models
16. Characterizing the biopharmaceutical classification system-based in vitro dissolution testing methodology for predicting in vivo bioavailability of generic drug formulations for American ANDA submissions
17. Investigating the freeze-drying cycle optimization strategies for preserving the stability and biological activity of a therapeutic protein formulation through lyophilization process analytical technology
18. Analyzing the solid-state characterization techniques — including X-ray powder diffraction and differential scanning calorimetry — for detecting crystalline polymorphic impurities in amorphous drug formulations
19. Developing a hydrogel-based transdermal drug delivery patch for continuous systemic drug delivery and characterizing its skin permeation rate and pharmacokinetic profile in ex vivo human skin models
20. Characterizing the dissolution rate and bioavailability implications of particle size reduction through nanomilling for a BCS Class II candidate using biorelevant dissolution media and rat in vivo studies

2. Pharmacokinetics and Pharmacodynamics

Pharmacokinetics and pharmacodynamics provide the quantitative framework for understanding how drugs are absorbed, distributed, metabolized, and eliminated and how drug concentrations relate to pharmacological effects — making this a foundational and methodologically sophisticated category of pharmacy thesis topics at American pharmacy schools and clinical pharmacology programs. Research here addresses population pharmacokinetic modeling, physiologically based pharmacokinetic simulation, drug-drug interactions, and the application of exposure-response relationships to dose optimization across diverse patient populations including children, elderly adults, and patients with organ impairment.

21. Investigating the population pharmacokinetic variability of vancomycin in American critically ill patients with augmented renal clearance using nonlinear mixed-effects modeling and Bayesian dose individualization
22. Analyzing the drug-drug interaction mechanisms between a novel kinase inhibitor and CYP3A4 substrates using in vitro microsomal incubation and in vivo pharmacokinetic study methodology
23. Developing a physiologically based pharmacokinetic model for predicting renal drug clearance changes across stages of chronic kidney disease for renally eliminated medications
24. Characterizing the exposure-response relationship between tacrolimus trough concentrations and acute rejection risk in American kidney transplant recipients using population pharmacodynamic modeling
25. Investigating the ontogeny of drug-metabolizing enzymes and transporters in American pediatric populations and their implications for age-appropriate dosing of commonly prescribed medications
26. Analyzing the pharmacokinetic alterations of antimicrobials in American morbidly obese patients using allometric scaling and body composition-based pharmacokinetic parameter estimation
27. Developing a model-informed precision dosing framework for aminoglycoside antibiotics in American neonatal intensive care unit patients using sparse sampling Bayesian estimation
28. Characterizing the hepatic first-pass extraction variability and its clinical consequences for oral bioavailability of high-extraction drugs in American patients with portosystemic shunting
29. Investigating the time-kill kinetics and pharmacodynamic target attainment for novel beta-lactam antibiotics against multidrug-resistant Enterobacteriaceae using in vitro dynamic infection models
30. Analyzing the pharmacokinetic-pharmacodynamic relationships governing QTc interval prolongation for a novel antipsychotic medication using compartmental modeling and cardiac safety biomarker data
31. Developing a population pharmacokinetic model for direct oral anticoagulants in American elderly patients with atrial fibrillation and evaluating the dose-exposure-bleeding risk relationship
32. Characterizing the transporter-mediated drug-drug interactions between metformin and commonly co-prescribed medications through OCT1 and MATE transporter inhibition studies
33. Investigating the sex differences in drug metabolism and pharmacokinetic parameters for commonly prescribed cardiovascular medications in American adults using clinical pharmacokinetic study data
34. Analyzing the pharmacodynamic target attainment probabilities for piperacillin-tazobactam against extended-spectrum beta-lactamase-producing organisms using Monte Carlo simulation and American antibiogram data
35. Developing a physiologically based pharmacokinetic model for predicting drug placental transfer and fetal exposure during pregnancy for medications commonly used by American pregnant women
36. Characterizing the intrinsic and extrinsic factors contributing to interindividual variability in warfarin dose requirements in American anticoagulation clinic populations using pharmacogenomic and clinical covariate analysis
37. Investigating the nonlinear pharmacokinetics and saturable protein binding of phenytoin in American epilepsy patients using individualized Michaelis-Menten parameter estimation from clinical concentration data
38. Analyzing the pharmacokinetic drug interactions between antiretroviral medications and commonly used over-the-counter supplements in American HIV-positive patients using clinical pharmacokinetic study design
39. Developing an optimal sampling strategy for area under the curve estimation of mycophenolic acid in American renal transplant patients using D-optimal design and simulation methodology
40. Characterizing the in vitro to in vivo extrapolation accuracy of human liver microsome and hepatocyte-based clearance predictions for a structurally diverse set of drugs using American FDA drug approval data

3. Clinical Pharmacy and Pharmacist-Led Care

Clinical pharmacy encompasses the direct patient care roles of pharmacists across American healthcare settings — from hospital inpatient services and ambulatory care clinics to community pharmacies and long-term care facilities — making this a practically important and outcomes-focused category of pharmacy thesis topics. Research here evaluates the effectiveness of pharmacist-led medication therapy management, comprehensive medication reviews, transitions of care services, chronic disease management programs, and pharmacist prescribing authority expansions across American healthcare. Graduate students contribute randomized trials, quasi-experimental evaluations, and qualitative studies demonstrating the clinical and economic value of expanded pharmacist roles in American healthcare delivery.

41. Investigating the effectiveness of pharmacist-led anticoagulation management services on time in therapeutic range and major bleeding event rates in American outpatient anticoagulation clinic populations
42. Analyzing the impact of clinical pharmacist participation in interdisciplinary rounds on antibiotic de-escalation rates and length of stay in American academic medical center intensive care units
43. Developing a pharmacist-delivered medication therapy management program for American Medicare Part D beneficiaries with diabetes and evaluating its effects on hemoglobin A1c and medication adherence
44. Characterizing the clinical outcomes of pharmacist prescribing authority for hormonal contraception in American states with collaborative practice agreements compared to states without such agreements
45. Investigating the effectiveness of pharmacist-led hypertension management programs in American federally qualified health centers on blood pressure control and cardiovascular risk reduction
46. Analyzing the medication error interception rates and patient safety outcomes attributable to clinical pharmacist participation in American hospital medication reconciliation programs at care transitions
47. Developing a transitions of care pharmacist service for American patients discharged following acute myocardial infarction and evaluating its impact on thirty-day readmission and medication adherence
48. Characterizing the drug-related problem identification rates and clinical intervention outcomes of comprehensive medication reviews conducted by American community pharmacists in Medicare Advantage populations
49. Investigating the effectiveness of pharmacist-led smoking cessation programs in American community pharmacy settings using a combination of nicotine replacement therapy and behavioral counseling
50. Analyzing the impact of pharmacist deprescribing interventions on potentially inappropriate medication reduction and fall-related hospitalization rates in American nursing home residents
51. Developing a pharmacist-led opioid risk assessment and naloxone co-prescription program for American patients initiating chronic opioid therapy in primary care settings
52. Characterizing the clinical pharmacist intervention patterns and acceptance rates for drug therapy problems identified during hospital-based pharmacist consultation services at American academic hospitals
53. Investigating the effectiveness of telepharmacy services for providing clinical pharmacy support to American critical access hospitals without on-site pharmacist staffing
54. Analyzing the impact of pharmacy-based point-of-care testing for hemoglobin A1c and lipids on diabetes and cardiovascular medication adjustment rates in American community pharmacy settings
55. Developing a pharmacist-delivered health literacy assessment and medication counseling protocol for American patients with limited health literacy initiating complex polypharmacy regimens
56. Characterizing the pharmacist prescribing practices and patient outcomes for travel health vaccines and medications dispensed under American state pharmacy collaborative practice agreements
57. Investigating the cost savings and clinical outcome improvements attributable to clinical pharmacy specialist services in American ambulatory oncology infusion centers
58. Analyzing the relationship between pharmacist staffing ratios and medication error rates in American hospital inpatient settings using national hospital staffing and safety event data
59. Developing a pharmacist-led post-discharge follow-up program for American heart failure patients using telehealth and remote monitoring to reduce medication-related readmissions
60. Characterizing the collaborative drug therapy management agreement utilization patterns and clinical outcomes across American state pharmacy practice environments with different prescriptive authority frameworks

4. Pharmacoepidemiology and Drug Safety

Pharmacoepidemiology applies epidemiological methods to the study of drug use and effects in large human populations, generating essential evidence about the real-world safety and effectiveness of medications that complements randomized trial data and informs American regulatory and clinical decisions. This category of pharmacy thesis topics draws on administrative claims databases, electronic health records, spontaneous adverse event reporting systems, and prospective cohort studies to characterize drug utilization patterns, identify safety signals, and evaluate comparative effectiveness. Graduate students at American pharmacy schools and schools of public health with pharmacoepidemiology programs contribute to the post-market drug safety evidence base that protects American patients.

61. Investigating the association between fluoroquinolone antibiotic exposure and aortic aneurysm risk in American adults using a self-controlled case series design with Medicare claims data
62. Analyzing the real-world comparative effectiveness of GLP-1 receptor agonists versus DPP-4 inhibitors for cardiovascular outcome prevention in American type 2 diabetes patients using propensity-matched claims analysis
63. Developing a disproportionality analysis methodology for detecting novel adverse drug reaction signals in the FDA Adverse Event Reporting System database using Bayesian data mining approaches
64. Characterizing the prescribing cascade patterns for commonly occurring drug-induced adverse effects in American elderly patients using national prescription claims and medical encounter data
65. Investigating the association between proton pump inhibitor long-term use and hypomagnesemia-related adverse events in American patients using a nested case-control study design
66. Analyzing the utilization trends and off-label prescribing patterns for GLP-1 receptor agonist medications in American non-diabetic populations using commercial insurance claims data
67. Developing a pharmacovigilance signal detection framework for real-world evidence generation from American electronic health record networks using distributed research methodology
68. Characterizing the drug-induced liver injury incidence and causality assessment patterns for newly approved medications in American FDA post-market surveillance reporting
69. Investigating the association between antidepressant use during pregnancy and neurodevelopmental outcomes in offspring using American Medicaid data with sibling-controlled confounding adjustment
70. Analyzing the opioid dose escalation patterns and transition to high-dose chronic opioid therapy risk factors in American workers’ compensation insurance populations using longitudinal claims data
71. Developing a database study methodology for evaluating the cardiovascular safety of non-steroidal anti-inflammatory drugs across American patient subgroups using active comparator new-user designs
72. Characterizing the medication adherence patterns and clinical outcome consequences for direct oral anticoagulants versus warfarin in American Medicare beneficiaries with atrial fibrillation
73. Investigating the association between benzodiazepine receptor agonist use and dementia risk in American adults over sixty using a target trial emulation approach with electronic health record data
74. Analyzing the drug utilization patterns and safety outcome monitoring practices for high-risk biologic medications in American rheumatology specialty pharmacy populations
75. Developing a population-based surveillance system for monitoring antimicrobial resistance emergence linked to antibiotic prescribing patterns across American ambulatory care settings
76. Characterizing the trimethoprim-sulfamethoxazole-associated hyperkalemia risk in American older adults co-prescribed with renin-angiotensin system inhibitors using administrative claims methodology
77. Investigating the association between statin use intensity and new-onset diabetes mellitus in American adults using an instrumental variable approach to address confounding by indication
78. Analyzing the COVID-19 vaccine safety surveillance signal detection and causality assessment methodology used in the American Vaccine Safety Datalink and V-safe monitoring systems
79. Developing a multi-database pharmacoepidemiological study protocol for evaluating the comparative safety of SGLT2 inhibitors and GLP-1 receptor agonists in American patients with heart failure
80. Characterizing the medication use patterns and adverse outcome rates for immunosuppressive therapy in American solid organ transplant recipients across different transplant center practice environments

5. Pharmacogenomics and Precision Pharmacy

Pharmacogenomics — the study of how genetic variation influences drug response, efficacy, and toxicity — is transforming pharmacy practice toward individualized medication selection and dosing, making it an intellectually exciting and clinically important category of pharmacy thesis topics at American pharmacy schools and genomic medicine programs. Research here addresses the implementation of pharmacogenomic testing in clinical settings, the discovery of novel pharmacogenomic biomarkers, the cost-effectiveness of genotype-guided prescribing, and the equity implications of pharmacogenomic programs that are developed primarily from European-ancestry populations. American academic medical centers with pharmacogenomics implementation programs are generating the evidence needed to bring precision pharmacy into routine clinical practice.

81. Investigating the clinical utility of preemptive CYP2C19 genotyping for antiplatelet therapy selection in American patients undergoing percutaneous coronary intervention using a pragmatic implementation study design
82. Analyzing the CYP2D6 metabolizer phenotype distribution and its relationship to opioid analgesic dosing requirements and adverse effect rates in American patients with chronic pain
83. Developing a pharmacogenomics clinical decision support tool for thiopurine dosing in American pediatric patients with acute lymphoblastic leukemia incorporating TPMT and NUDT15 genotype data
84. Characterizing the HLA-B genotype-associated severe cutaneous adverse reaction risk for allopurinol in American patients from Asian ancestry backgrounds compared to European ancestry populations
85. Investigating the implementation barriers and facilitators for pharmacogenomics-guided prescribing programs at American community hospitals without dedicated clinical pharmacogenomics infrastructure
86. Analyzing the cost-effectiveness of panel-based preemptive pharmacogenomic testing programs in American primary care settings using decision modeling across different testing panel compositions
87. Developing a pharmacogenomics education curriculum for American pharmacy students and evaluating its effectiveness in improving genotype-phenotype interpretation competency and clinical application skills
88. Characterizing the SLCO1B1 pharmacogenomic variant prevalence and its association with statin-induced myopathy risk across racially diverse American patient populations receiving high-intensity statin therapy
89. Investigating the clinical validity and utility of pharmacogenomic testing for antidepressant selection in American adults with major depressive disorder using a randomized clinical trial design
90. Analyzing the ancestry-based limitations of current pharmacogenomic variant databases for predicting drug response in American patients of African, Hispanic, and Asian ancestry
91. Developing a return of pharmacogenomic results protocol for American biobank participants and evaluating patient comprehension, psychological impact, and medication adherence behavior change
92. Characterizing the CYP3A5 genotype distribution and tacrolimus dose requirement differences across racial groups in American kidney transplant recipients and their equity implications for standard dosing protocols
93. Investigating the pharmacogenomic predictors of immune-related adverse events from checkpoint inhibitor immunotherapy in American oncology patients using genome-wide association study methodology
94. Analyzing the clinical pharmacy workflow integration requirements for pharmacogenomic consultation services at American academic medical centers implementing preemptive genotyping programs
95. Developing a multi-gene pharmacogenomic risk score for predicting antipsychotic-induced metabolic side effects in American patients with serious mental illness initiating second-generation antipsychotic therapy
96. Characterizing the patient perspectives on pharmacogenomic testing acceptance, information preferences, and privacy concerns across demographic groups in American ambulatory care settings
97. Investigating the warfarin pharmacogenomic dosing algorithm performance across racially diverse American anticoagulation clinic populations compared to clinical factor-based dosing approaches
98. Analyzing the pharmacogenomic variant annotation accuracy and clinical interpretation consistency across American commercial pharmacogenomic testing laboratory reports
99. Developing a pharmacist-led pharmacogenomics consultation service at an American academic medical center and evaluating its clinical impact on drug selection, dosing appropriateness, and adverse event rates
100. Characterizing the long-term clinical outcomes and healthcare utilization differences between American patients who received pharmacogenomics-guided versus standard antidepressant prescribing using propensity-matched cohort methodology

6. Antimicrobial Pharmacy and Stewardship

Antimicrobial stewardship has become one of the most critical programmatic priorities in American pharmacy practice, as rising antimicrobial resistance, Clostridioides difficile infection, and the depletion of the antibiotic development pipeline create urgent needs for evidence-based optimization of antibiotic prescribing across hospital and outpatient settings. This category of pharmacy thesis topics encompasses antimicrobial stewardship program design, pharmacist-led antibiotic management, resistance epidemiology, antifungal stewardship, and the development of novel approaches to restoring antibiotic efficacy. Graduate students at American schools of pharmacy with infectious diseases pharmacy specialization contribute to both the science of resistance and the implementation of stewardship programs that protect antibiotic effectiveness for future generations.

101. Investigating the impact of pharmacist-led prospective audit and feedback antimicrobial stewardship interventions on antibiotic days of therapy and Clostridioides difficile infection rates in American community hospitals
102. Analyzing the antibiotic prescribing appropriateness for common respiratory tract infections in American urgent care and telehealth settings using electronic health record audit methodology
103. Developing an antibiotic allergy assessment and de-labeling program led by pharmacists and allergists at an American academic medical center and evaluating its impact on beta-lactam utilization
104. Characterizing the antifungal stewardship program outcomes and candidemia mortality rates before and after pharmacist-led antifungal optimization interventions at American transplant and oncology centers
105. Investigating the pharmacokinetic-pharmacodynamic target attainment for continuous versus intermittent infusion beta-lactam dosing strategies against resistant gram-negative organisms in American ICU patients
106. Analyzing the procalcitonin-guided antibiotic discontinuation protocol adherence and antibiotic duration reduction outcomes in American medical intensive care unit patients
107. Developing a clinical decision support tool for empirical antibiotic selection based on local antibiogram data integrated into American hospital electronic health record ordering systems
108. Characterizing the outpatient antibiotic prescribing variation across American primary care physician specialties for uncomplicated urinary tract infections using Medicare Part D prescription data
109. Investigating the effectiveness of pharmacist-driven intravenous to oral antibiotic conversion programs on treatment outcomes and hospital length of stay in American inpatient settings
110. Analyzing the relationship between antibiotic stewardship program infrastructure and process metrics and patient outcome measures including mortality and length of stay across American hospitals
111. Developing a telepharmacy-delivered antimicrobial stewardship consultation service for American critical access hospitals lacking on-site infectious diseases pharmacy specialists
112. Characterizing the carbapenem-sparing antibiotic regimen effectiveness and safety for treating extended-spectrum beta-lactamase-producing organism infections in American hospital settings
113. Investigating the impact of antibiotic stewardship education interventions on prescribing knowledge and behavior change among American emergency medicine residents and attending physicians
114. Analyzing the real-world effectiveness and nephrotoxicity rates of ceftazidime-avibactam for carbapenem-resistant Enterobacteriaceae infections in American academic medical center patients
115. Developing a risk stratification tool for identifying American patients with methicillin-resistant Staphylococcus aureus bacteremia at highest risk for treatment failure using pharmacokinetic and microbiological variables
116. Characterizing the antibiotic prescribing patterns for asymptomatic bacteriuria in American long-term care facility residents and the effectiveness of pharmacist-led guideline implementation programs
117. Investigating the pharmacodynamic optimization strategies for polymyxin B dosing against multidrug-resistant gram-negative organisms in American patients with limited therapeutic alternatives
118. Analyzing the antifungal prophylaxis prescribing patterns and breakthrough fungal infection rates in American hematologic malignancy patients undergoing allogeneic stem cell transplantation
119. Developing a quality metrics dashboard for antimicrobial stewardship program performance monitoring and benchmarking across American hospital systems participating in national stewardship networks
120. Characterizing the patient and provider perspectives on antibiotic stewardship communication strategies for reducing antibiotic demand for viral respiratory infections in American primary care settings

7. Social and Administrative Pharmacy

Social and administrative pharmacy examines the behavioral, social, organizational, and economic dimensions of medication use and pharmacy practice — making it a broadly applicable category of pharmacy thesis topics for graduate students interested in health disparities, medication adherence, pharmacy workforce, drug policy, and the social determinants of medication access across American communities. Research here draws on health behavior theory, econometrics, qualitative methodology, and implementation science to understand how patients, providers, organizations, and policies shape medication use patterns and outcomes across diverse American populations.

121. Investigating the relationship between cost-related medication nonadherence and emergency department visits and hospitalizations among American adults with type 2 diabetes using nationally representative survey data
122. Analyzing the racial and ethnic disparities in medication adherence for hypertension and hyperlipidemia in American adults using pharmacy claims data linked to electronic health records
123. Developing a financial assistance navigation program for American patients prescribed high-cost specialty medications and evaluating its impact on time to treatment initiation and adherence
124. Characterizing the impact of pharmacy deserts on medication adherence and chronic disease control in low-income American urban and rural communities using geographic information system methodology
125. Investigating the effectiveness of motivational interviewing by American community pharmacists for improving medication adherence in patients with poorly controlled chronic conditions
126. Analyzing the pharmacy benefit design features — including copayment levels, formulary tier placement, and prior authorization requirements — associated with specialty medication adherence in American commercial insurance populations
127. Developing a patient-centered medication use experience assessment framework for evaluating pharmacy service quality across American retail, specialty, and ambulatory care pharmacy settings
128. Characterizing the implicit bias patterns in American pharmacist interactions with minority patients and their relationship to medication counseling quality and patient satisfaction
129. Investigating the opioid prescribing rate changes in American states following the implementation of prescription drug monitoring program mandatory check requirements using interrupted time series analysis
130. Analyzing the pharmacy workforce geographic maldistribution patterns across American rural counties and their relationship to medication adherence and chronic disease outcome disparities
131. Developing a medication synchronization program evaluation framework for American community pharmacies and assessing its impact on medication adherence and pharmacy workflow efficiency
132. Characterizing the health literacy-appropriate medication counseling practices of American community pharmacists using standardized patient methodology across pharmacy settings
133. Investigating the relationship between pharmacy ownership type — chain versus independent versus grocery — and medication counseling quality and patient satisfaction in American community pharmacy settings
134. Analyzing the impact of state naloxone standing order policies on community pharmacy naloxone dispensing rates and opioid overdose mortality in American counties with high opioid burden
135. Developing a community pharmacy-based social determinants of health screening and referral program for American patients with medication adherence challenges related to social needs
136. Characterizing the medication management challenges and pharmacy service needs of American family caregivers managing complex medication regimens for dependent elderly relatives
137. Investigating the effectiveness of digital adherence packaging systems on medication adherence and clinical outcomes in American older adults with polypharmacy and cognitive impairment
138. Analyzing the prescription abandonment patterns at American specialty pharmacies and identifying the patient, drug, and benefit design factors most strongly associated with treatment non-initiation
139. Developing an economic evaluation of comprehensive medication management services in American accountable care organizations using claims-based outcome and cost measurement methodology
140. Characterizing the telepharmacy service models and their impact on pharmacy access, medication counseling quality, and patient outcomes in American underserved rural communities

8. Oncology Pharmacy

Oncology pharmacy has grown into a highly specialized clinical and research domain as cancer treatment complexity increases with targeted therapies, immunotherapies, and combination regimens requiring sophisticated dosing, toxicity management, and patient education — making it a growing category of pharmacy thesis topics at American cancer centers and pharmacy residency programs. Research here addresses chemotherapy dosing optimization, oral oncology medication adherence, immunotherapy toxicity management, pharmacist-led supportive care, and the health economics of cancer drug use. Graduate students contribute evidence that directly informs the medication management of American cancer patients across inpatient, outpatient infusion, and oral oncology care settings.

141. Investigating the pharmacist-led oral oncology medication adherence program effectiveness on treatment persistence and clinical outcomes in American patients with chronic myeloid leukemia on tyrosine kinase inhibitors
142. Analyzing the immune-related adverse event incidence, management patterns, and pharmacist intervention outcomes for checkpoint inhibitor therapy across American academic oncology infusion centers
143. Developing a clinical pharmacist-led comprehensive medication management program for American cancer patients on complex multimodal therapy regimens and evaluating its impact on drug-related problems
144. Characterizing the weight-based versus fixed dosing outcomes for monoclonal antibody oncology therapies in American obese patients across tumor types using pharmacokinetic-pharmacodynamic modeling
145. Investigating the pharmacogenomic predictors of fluorouracil toxicity in American colorectal cancer patients using DPYD variant genotyping and plasma dihydrouracil measurement methodology
146. Analyzing the real-world effectiveness and safety of biosimilar filgrastim compared to reference filgrastim for chemotherapy-induced neutropenia prevention in American oncology practice
147. Developing a clinical decision support tool for individualized carboplatin dosing using Calvert formula with CKD-EPI-based renal function estimation in American ambulatory cancer treatment centers
148. Characterizing the drug interaction burden and pharmacist intervention rates in American cancer patients receiving concurrent targeted therapy and commonly prescribed non-oncology medications
149. Investigating the financial toxicity and cost-related oral chemotherapy adherence consequences for American cancer patients with Medicare Part D coverage gap exposure
150. Analyzing the supportive care medication utilization patterns and antiemetic guideline adherence rates across American outpatient chemotherapy infusion centers using pharmacy dispensing data
151. Developing a pharmacist-led toxicity monitoring and early intervention protocol for American patients receiving PARP inhibitor therapy for ovarian and breast cancer
152. Characterizing the medication reconciliation accuracy and drug-related problem identification rates at cancer treatment initiation in American oncology patients with multiple comorbidities
153. Investigating the clinical pharmacist impact on time to antibiotic administration and appropriate empirical regimen selection for febrile neutropenia episodes in American inpatient oncology settings
154. Analyzing the oral chemotherapy copayment assistance program utilization patterns and their impact on treatment initiation and adherence in American patients with inadequate prescription drug coverage
155. Developing a pharmacist-delivered oral chemotherapy patient education and monitoring program for American community oncology practices without clinical pharmacy specialist staffing
156. Characterizing the opioid rotation outcomes and pain control quality in American cancer patients with inadequate pain control managed by oncology clinical pharmacists using equianalgesic dosing protocols
157. Investigating the real-world comparative effectiveness of PD-1 versus PD-L1 checkpoint inhibitors for non-small cell lung cancer in American patients using electronic health record data
158. Analyzing the clinical pharmacy consultation impact on chemotherapy dose modification appropriateness and toxicity management in American patients with organ dysfunction receiving cytotoxic therapy
159. Developing a remote patient monitoring program for early detection of oral chemotherapy toxicity in American cancer patients using electronic patient-reported outcome assessment platforms
160. Characterizing the palliative care medication management practices and symptom control outcomes in American cancer patients transitioned to hospice pharmacy services

9. Geriatric Pharmacy and Polypharmacy

Polypharmacy and medication-related problems in older adults represent one of the most significant patient safety challenges in American healthcare, as the average Medicare beneficiary takes multiple prescription medications, increasing the risk of adverse drug events, drug-drug interactions, inappropriate prescribing, and medication non-adherence — making geriatric pharmacy a clinically important category of pharmacy thesis topics. Research here addresses Beers Criteria-based prescribing quality, deprescribing interventions, medication reconciliation in care transitions, and the pharmacokinetic consequences of aging on drug disposition. Graduate students at American pharmacy schools contribute evidence that informs medication safety policy and clinical practice for the growing elderly American population.

161. Investigating the prevalence and clinical consequences of potentially inappropriate medication prescribing according to Beers Criteria in American community-dwelling adults over seventy-five using Medicare claims data
162. Analyzing the deprescribing intervention effectiveness for reducing fall-causing medications in American nursing home residents with a history of falls using a cluster-randomized trial design
163. Developing a pharmacist-led comprehensive medication review program for American older adults with polypharmacy in primary care and evaluating its impact on medication appropriateness and quality of life
164. Characterizing the drug-drug interaction burden and associated adverse drug event rates in American Medicare beneficiaries with five or more chronic conditions using prescription claims analysis
165. Investigating the anticholinergic medication burden and its relationship to cognitive decline and dementia incidence in American older adults using longitudinal electronic health record data
166. Analyzing the medication reconciliation error patterns and their clinical consequences during care transitions between acute care, skilled nursing facility, and home settings in American elderly populations
167. Developing a patient-centered deprescribing decision aid for American older adults and their physicians for making informed decisions about stopping potentially inappropriate long-term medications
168. Characterizing the pharmacokinetic consequences of age-related body composition changes, reduced renal function, and decreased hepatic blood flow on drug exposure in American adults over eighty
169. Investigating the relationship between medication regimen complexity index scores and medication adherence rates in American older adults with multimorbidity using pharmacy dispensing data
170. Analyzing the opioid prescribing appropriateness and opioid-related adverse event rates in American nursing home residents receiving palliative and non-palliative pain management
171. Developing a pharmacist-led medication management home visit program for high-risk American older adults recently discharged from hospital and evaluating its readmission prevention effectiveness
172. Characterizing the proton pump inhibitor overprescribing patterns and deprescribing success rates in American long-term care facilities using pharmacist-led medication review methodology
173. Investigating the impact of pharmacist participation in American geriatric care team rounds on potentially inappropriate prescribing reduction and thirty-day hospital readmission rates
174. Analyzing the health literacy and cognitive capacity barriers to medication self-management in American older adults with polypharmacy using validated assessment tools in primary care settings
175. Developing a pharmacogenomic dosing consideration framework for high-risk medications in American elderly patients accounting for both age-related pharmacokinetic changes and CYP enzyme genotype

10. Pharmacy Education and Workforce

Pharmacy education and workforce development encompass the preparation of pharmacy graduates for evolving clinical roles, the assessment of educational competencies, faculty development, and the health equity dimensions of the American pharmacy workforce — making this an important category of pharmacy thesis topics for graduate students with interests in health professions education and workforce policy. Research here addresses Doctor of Pharmacy curriculum design, interprofessional education, simulation training, the assessment of clinical reasoning, and the structural barriers affecting workforce diversity and geographic distribution in American pharmacy.

176. Investigating the relationship between American pharmacy student performance on integrated pharmacy curriculum assessments and first-attempt NAPLEX licensure examination pass rates
177. Analyzing the interprofessional education experience quality and collaborative practice attitude development in American pharmacy and medical students completing shared patient care simulation exercises
178. Developing a standardized patient simulation program for American pharmacy students to practice motivational interviewing and medication adherence counseling skills and evaluating its competency outcomes
179. Characterizing the implicit bias awareness and cultural humility development in American Doctor of Pharmacy students following structured diversity, equity, and inclusion curriculum integration
180. Investigating the effectiveness of flipped classroom instructional models for pharmacokinetics and pharmacotherapy courses in American pharmacy schools compared to traditional lecture-based instruction
181. Analyzing the geographic distribution of American pharmacy graduates relative to community pharmacy need and identifying the training program factors associated with rural practice career selection
182. Developing a clinical reasoning assessment framework for American pharmacy students and residents using validated think-aloud protocol methodology across complex patient medication management cases
183. Characterizing the American pharmacy residency training program capacity and match rate trends and their relationship to the growing supply of Doctor of Pharmacy graduates seeking postgraduate training
184. Investigating the burnout prevalence and contributing organizational factors among American community and clinical pharmacists across different practice settings and pharmacy ownership models
185. Analyzing the pharmacy technician training and certification program quality variation across American states and its relationship to dispensing accuracy and patient safety outcomes
186. Developing a pharmaceutical care competency assessment rubric for American advanced pharmacy practice experience preceptors that ensures consistent student performance evaluation across diverse clinical sites
187. Characterizing the diversity pipeline program effectiveness for increasing underrepresented minority enrollment and retention in American Doctor of Pharmacy programs
188. Investigating the relationship between American pharmacy school research training curriculum intensity and graduate research productivity, PhD program enrollment, and academic career pursuit rates
189. Analyzing the impact of telehealth skill training integration into American Doctor of Pharmacy experiential education on student readiness for virtual patient care delivery
190. Developing a faculty development program for American pharmacy school preceptors focused on evidence-based teaching strategies and evaluating its impact on student learning outcomes
191. Characterizing the knowledge, attitudes, and skill gaps of American newly licensed pharmacists for providing pharmacogenomics-guided medication counseling in clinical practice settings
192. Investigating the effectiveness of case-based learning modules incorporating health equity principles for improving American pharmacy student patient communication across culturally diverse populations
193. Analyzing the opioid education and naloxone dispensing training curriculum content across American Doctor of Pharmacy programs and its relationship to graduate naloxone counseling practice behaviors
194. Developing a longitudinal pharmacy student professional identity formation assessment framework for American pharmacy programs aligned with patient care-centered pharmacist role expectations
195. Characterizing the American pharmacy residency program director perspectives on the evolving clinical pharmacist competencies required for advanced practice roles in primary care and ambulatory settings
196. Investigating the scholarship of teaching and learning research productivity patterns among American pharmacy school faculty and identifying the institutional supports most associated with educational research output
197. Analyzing the American pharmacy workforce gender distribution trends across clinical specialist, faculty, and leadership roles and identifying structural barriers to advancement for women pharmacists
198. Developing a transition to practice mentorship program for American new graduate pharmacists entering clinical specialist roles and evaluating its impact on professional confidence and job retention
199. Characterizing the continuing professional development needs and self-assessment accuracy of American licensed pharmacists across different practice settings using portfolio-based competency mapping methodology
200. Investigating the relationship between American pharmacy school accreditation standards compliance and graduate competency outcomes including NAPLEX performance, residency match rates, and employer satisfaction ratings

The Range of Pharmacy Thesis Topics

Current Issues

The opioid epidemic remains one of the most devastating pharmaceutical policy failures in American history, with hundreds of thousands of deaths attributable to prescription opioid overprescribing, heroin transition, and illicitly manufactured fentanyl over the past two decades. Pharmacy has been both implicated in and central to the response to this crisis — from the prescribing culture and dispensing practices that contributed to initial overprescribing to the expanding role of pharmacists in naloxone distribution, medication-assisted treatment with buprenorphine, and prescription drug monitoring program compliance. Pharmacy thesis topics addressing opioid stewardship, naloxone access equity, buprenorphine prescribing barriers, and the pharmacist’s role in addiction medicine represent some of the most socially consequential research available to graduate students in the discipline.

Antimicrobial resistance represents a slow-moving but potentially catastrophic public health emergency that positions pharmacy at the center of both the problem and its solution. American pharmacists are uniquely positioned to optimize antibiotic prescribing across hospital and outpatient settings, implement stewardship programs, counsel patients on antibiotic completion and appropriate use, and contribute to the surveillance infrastructure needed to monitor resistance emergence. Yet the evidence base for specific stewardship interventions across diverse American practice settings remains incomplete, and the pipeline of novel antibiotics is dangerously thin relative to the pace of resistance development. Graduate students developing pharmacy thesis topics in antimicrobial stewardship and resistance contribute to one of the field’s most urgent scientific and public health priorities.

Medication affordability has become a defining equity challenge in American pharmacy, as the high prices of specialty biologics, novel oncology agents, and even generic drug shortages price essential medications out of reach for millions of Americans without adequate prescription drug coverage. Cost-related medication nonadherence — patients rationing, skipping, or abandoning prescribed medications because of cost — translates directly into preventable hospitalizations, disease complications, and premature death that fall disproportionately on low-income, uninsured, and underinsured American patients. Pharmacy thesis topics that document the scope of medication affordability barriers, evaluate the effectiveness of patient assistance programs, and analyze the policy levers most likely to improve drug pricing transparency and access contribute to this central equity challenge in American healthcare.

Recent Trends

The expansion of pharmacist clinical roles through collaborative practice agreements, pharmacist prescribing authority legislation, and provider status recognition at the state level is reshaping the scope of American pharmacy practice and generating important research questions about the outcomes, safety, and cost-effectiveness of these expanded roles. American pharmacists are now independently prescribing hormonal contraception, initiating and managing treatment for hypertension and diabetes, prescribing naloxone and buprenorphine, and ordering and interpreting point-of-care tests in settings ranging from community pharmacies to physician offices to hospital inpatient services. Graduate students developing pharmacy thesis topics that rigorously evaluate the clinical impact of expanded pharmacist scope of practice contribute to the evidence base that will determine the future trajectory of pharmacist authority in American healthcare.

Precision pharmacotherapy driven by pharmacogenomics is transitioning from research aspiration to clinical implementation at an accelerating pace across American academic medical centers, with preemptive genotyping panels enabling proactive medication optimization before drugs are even prescribed. The Clinical Pharmacogenomics Implementation Consortium guidelines provide actionable genotype-phenotype recommendations for dozens of gene-drug pairs, and American health systems are developing the electronic health record infrastructure, clinical decision support tools, and pharmacist consultation services needed to operationalize these recommendations at scale. Research evaluating the implementation effectiveness, clinical impact, and equity implications of pharmacogenomics programs represents one of the most productive frontiers in contemporary pharmacy thesis topics.

Future Directions

Artificial intelligence and machine learning are beginning to transform pharmaceutical sciences and clinical pharmacy in ways that will define the next generation of pharmacy thesis topics. In drug development, AI-assisted molecular design, toxicity prediction, and clinical trial optimization are accelerating the identification of promising drug candidates and reducing development costs. In clinical pharmacy, machine learning models are being developed for adverse drug event prediction, optimal antibiotic selection, and personalized medication dosing that adjusts to individual patient response patterns in real time. Graduate students at American pharmacy schools who develop computational skills alongside pharmaceutical and clinical expertise will be exceptionally well-positioned to contribute to this rapidly evolving frontier.

The pharmacist’s role in public health and prevention will expand significantly in coming years as American healthcare systems seek cost-effective approaches to population health management that leverage the accessibility and clinical expertise of community and ambulatory care pharmacists. Future pharmacy thesis topics will evaluate pharmacist-delivered vaccination programs, chronic disease screening, tobacco cessation, and social determinants of health navigation across community pharmacy settings — generating evidence about how pharmacy networks can be integrated into American public health infrastructure to reach populations with limited access to physician-based primary care. As the largest brick-and-mortar healthcare presence in many American communities, pharmacies represent an underutilized but potentially transformative platform for population health intervention.

Conclusion

The 200 pharmacy thesis topics presented across these ten categories reflect the extraordinary breadth of a discipline that spans molecular drug formulation and population-level pharmacoepidemiology, precision pharmacogenomics and antimicrobial stewardship, oncology pharmacy and geriatric deprescribing, social pharmacy and workforce development. Students pursuing pharmacy thesis topics at American universities engage with research questions that matter directly to the safety, effectiveness, and equity of medication use across the full spectrum of American healthcare. Career pathways extend into academic pharmacy, pharmaceutical industry research, regulatory science at the FDA, clinical pharmacy specialist practice, health policy, and public health — all domains where rigorously trained pharmacy scholars make lasting contributions to the science and practice of medication therapy.

Academic Support

iResearchNet provides expert academic support for graduate students developing pharmacy thesis topics across the full range of this discipline’s scientific and clinical dimensions. Our consultants bring specialized expertise in pharmaceutical sciences, pharmacokinetics, clinical pharmacy, pharmacoepidemiology, pharmacogenomics, antimicrobial stewardship, oncology pharmacy, geriatric pharmacy, social and administrative pharmacy, and pharmacy education — with direct experience supporting students in American Doctor of Pharmacy, pharmaceutical sciences PhD, and health outcomes research doctoral programs. Whether you are designing a population pharmacokinetic model, developing a community pharmacy intervention study, analyzing prescription claims data, or building a pharmacogenomics implementation evaluation, iResearchNet’s support is oriented toward strengthening your scholarly development and deepening your engagement with pharmacy as a research discipline. Our mission is to support your intellectual growth, not to substitute for the original thinking that defines excellent graduate scholarship in pharmacy.